191 related articles for article (PubMed ID: 34419961)
1. Asynchrony of primary tumor and mediastinal lymph nodes response after neoadjuvant immunotherapy plus chemotherapy in a patient with stage IIIA non-small-cell lung cancer: a case report.
Liu Y; Gao Z; Zhang C; Liu X; Liu Z; Lin X; Qian B; Jin F; Shao G; Yang Z
Anticancer Drugs; 2022 Jan; 33(1):e784-e788. PubMed ID: 34419961
[TBL] [Abstract][Full Text] [Related]
2. [Remission rate of mediastinal lymph nodes after multimodal therapy of lung cancer--is it a prognostic factor?].
Granetzny A; Striehn E; Bosse U; Wagner W; Koch O; Vogt U; Froeschle P; Klinke F
Zentralbl Chir; 2003 Aug; 128(8):640-4. PubMed ID: 12931258
[TBL] [Abstract][Full Text] [Related]
3. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
Betticher DC; Hsu Schmitz SF; Tötsch M; Hansen E; Joss C; von Briel C; Schmid RA; Pless M; Habicht J; Roth AD; Spiliopoulos A; Stahel R; Weder W; Stupp R; Egli F; Furrer M; Honegger H; Wernli M; Cerny T; Ris HB
J Clin Oncol; 2003 May; 21(9):1752-9. PubMed ID: 12721251
[TBL] [Abstract][Full Text] [Related]
4. Comparison of mediastinal lymph node status and relapse pattern in clinical stage IIIA non-small cell lung cancer patients treated with neoadjuvant chemotherapy versus upfront surgery: A single center experience.
Savic M; Kontic M; Ercegovac M; Stojsic J; Bascarevic S; Moskovljevic D; Kostic M; Vesovic R; Popevic S; Laban M; Markovic J; Jovanovic D
Thorac Cancer; 2017 Sep; 8(5):393-401. PubMed ID: 28671758
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.
Eichhorn F; Klotz LV; Bischoff H; Thomas M; Lasitschka F; Winter H; Hoffmann H; Eichhorn ME
BMC Cancer; 2019 May; 19(1):413. PubMed ID: 31046714
[TBL] [Abstract][Full Text] [Related]
6. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology.
Ryu JS; Choi NC; Fischman AJ; Lynch TJ; Mathisen DJ
Lung Cancer; 2002 Feb; 35(2):179-87. PubMed ID: 11804691
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of regressive changes in the lung carcinoma lymphatic metastases following induction chemotherapy].
Klein J; Tichý T; Král V; Neoral C; Bohanes T; Szkorupa M; Kolek V; Herman M; Janásková T
Rozhl Chir; 2007 Apr; 86(4):206-11. PubMed ID: 17626464
[TBL] [Abstract][Full Text] [Related]
8. Surgical perspective in neoadjuvant chemoimmunotherapy for stage II-III non-small cell lung cancer.
Hong T; Sun T; Zhang M; Liu X; Yuan Y; Dolo PR; Chen B; Zhang H
Thorac Cancer; 2021 Oct; 12(20):2796-2802. PubMed ID: 34463034
[TBL] [Abstract][Full Text] [Related]
9. Pathological complete response to neoadjuvant chemoimmunotherapy correlates with peripheral blood immune cell subsets and metastatic status of mediastinal lymph nodes (N2 lymph nodes) in non-small cell lung cancer.
Ma T; Wen T; Cheng X; Wang Y; Wei P; Yang B; Yi L; Wang X; Yan Z; Wang J; Liu Z
Lung Cancer; 2022 Oct; 172():43-52. PubMed ID: 35988509
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of the treatment (neoadjuvant chemotherapy and surgery) in IIb and IIIa stages of non-small cell lung cancer].
Ptaszek B; Chabowski M; Wiatr E; Orłowski TM; Langfort R; Bestry I; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2006; 74(2):171-8. PubMed ID: 17269365
[TBL] [Abstract][Full Text] [Related]
11. [Multimodal treatment of non small cell lung cancer].
Stoelben E; Digel W; Henke M; Passlick B
Zentralbl Chir; 2006 Apr; 131(2):110-4. PubMed ID: 16612776
[TBL] [Abstract][Full Text] [Related]
12. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer.
Tfayli A; Al Assaad M; Fakhri G; Akel R; Atwi H; Ghanem H; El Karak F; Farhat F; Al Rabi K; Sfeir P; Youssef P; Mansour Z; Assi H; Haidar M; Abi Ghanem A; Khalifeh I; Boulos F; Mahfouz R; Youssef B; Zeidan Y; Bejjany R; Khuri F
Cancer Med; 2020 Nov; 9(22):8406-8411. PubMed ID: 32991781
[TBL] [Abstract][Full Text] [Related]
14. Combining antiangiogenic therapy with neoadjuvant chemotherapy increases treatment efficacy in stage IIIA (N2) non-small cell lung cancer without increasing adverse effects.
Zhao X; Su Y; You J; Gong L; Zhang Z; Wang M; Zhao Z; Zhang Z; Li X; Wang C
Oncotarget; 2016 Sep; 7(38):62619-62626. PubMed ID: 27566586
[TBL] [Abstract][Full Text] [Related]
15. Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer.
Hill A; Gong J; Wilczynski S; Mirza R; Erhunmwunsee L; Salgia R
J Oncol Pract; 2018 Sep; 14(9):569-571. PubMed ID: 30044685
[No Abstract] [Full Text] [Related]
16. [Two patterns of mediastinal lymph node resection for non-small cell lung cancer of stage IIIA: survival analysis of 219 cases].
Zhang GQ; Han F; Gao SL; A DL; Pang ZL
Ai Zheng; 2007 May; 26(5):519-23. PubMed ID: 17672944
[TBL] [Abstract][Full Text] [Related]
17. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced Non-Small-Cell Lung Cancer in a Patient with a History of Breast Cancer: A Case Report.
Yang RX; Hei Y; Zhu WT; Wang QR; Zhang HM; Chen Y
Curr Oncol; 2022 Aug; 29(9):6203-6210. PubMed ID: 36135056
[TBL] [Abstract][Full Text] [Related]
19. [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition].
Lücke E; Ganzert C; Föllner S; Wäsche A; Jechorek D; Schoeder V; Walles T; Genseke P; Schreiber J
Pneumologie; 2020 Nov; 74(11):766-772. PubMed ID: 32820489
[TBL] [Abstract][Full Text] [Related]
20. [Non-small cell lung cancer (NSCLC) stage IIIA/IIIB. A pilot study of neoadjuvant chemotherapy with paclitaxel and carboplatin].
Ukena D; Leutz M; Schlimmer P; Huwer H; Schäfers HJ; Sybrecht G
Med Klin (Munich); 1997 Dec; 92 Suppl 5():49-53. PubMed ID: 19479398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
